
    
      Trametinib and pazopanib are independently approved for other cancers. Both drugs work to
      inhibit tumor development in different ways. Combining these drugs may lead to improved
      disease control. The purpose of this study is to evaluate the effect of the combination of
      both drugs on advanced gastrointestinal stromal tumors.
    
  